Stay updated on Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial page.

Latest updates to the Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial page
- Check6 days agoChange DetectedThe page’s footer software/version label was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” indicating a non-content site update.SummaryDifference0.0%

- Check13 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check42 days agoChange DetectedThe page's revision label updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check56 days agoChange DetectedRevision: v3.4.3 replaces v3.4.2. This appears to be a minor version update with no visible changes to study content.SummaryDifference0.0%

- Check78 days agoChange DetectedFallopian tube cancer was added to the conditions list and Genetic and Rare Diseases Information Center resources were added. The page revision was updated from v3.4.1 to v3.4.2.SummaryDifference0.2%

- Check85 days agoChange DetectedRevision tag updated from v3.4.0 to v3.4.1. No visible changes to the study details were observed.SummaryDifference0.0%

Stay in the know with updates to Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial page.